Rhodiola Rosea Therapy of Major Depressive Disorder

Status: Completed
Location: See location...
Intervention Type: Other, Dietary Supplement, Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

Prior research has shown that Rhodiola rosea may be an effective, short-term, anti-depressant therapy. This study will examine the anti-depressant effect of Rhodiola rosea vs. a conventional, anti-depressant drug in the treatment of major depression.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: No
View:

• Men and women (all races and ethnicity) ≥ 18 years old

• DSM IV Axis I diagnosis of mild to moderate Major Depressive Disorder

• Baseline CGI/S rating of 3 ('mild') or 4 ('moderate')

• Baseline Hamilton Depression Rating score ≥ 10

• Not receiving other antidepressant therapy

• Able to provide signed informed consent

Locations
United States
Pennsylvania
Depression Research Unit
Philadelphia
Time Frame
Start Date: June 2010
Completion Date: July 2013
Participants
Target number of participants: 58
Treatments
Experimental: Rhodiola rosea
Herbal extract
Active Comparator: Sertraline
Conventional anti-depressant
Placebo Comparator: Sugar pill
Lactose monohydrate
Authors
Related Therapeutic Areas
Sponsors
Leads: University of Pennsylvania
Collaborators: National Center for Complementary and Integrative Health (NCCIH)

This content was sourced from clinicaltrials.gov

Similar Clinical Trials